FDA Eyes Testosterone Expansion as GLP-1 Rivals Emerge

The FDA is exploring whether testosterone therapy indications could be expanded to include low libido in women, a move that would formalize a clinical use currently handled largely off-label. The agency's interest signals a potential shift in how it evaluates hormonal treatments for female sexual dysfunction, a category with limited approved options. Separately, the GLP-1 drug class faces an emerging scientific challenge: researchers who helped establish GLP-1 as the dominant obesity target are now arguing that dual GIP-glucagon pathways may deliver comparable or superior weight loss with fewer side effects, including reduced nausea and fewer dosing constraints. That debate carries direct commercial weight as the obesity drug market expands. Against that backdrop, Kailera Therapeutics completed the largest-ever IPO for a drug company, raising $625 million. Kailera is advancing obesity drugs licensed from China, entering a market where the durability of GLP-1 dominance is now actively contested by early-stage animal data pointing toward alternative mechanisms.